{"id":"https://openalex.org/W4411907752","doi":"https://doi.org/10.1158/1078-0432.c.7903394","title":"Data from Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Na\u00efve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study","display_name":"Data from Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Na\u00efve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study","publication_year":2025,"publication_date":"2025-07-01","ids":{"openalex":"https://openalex.org/W4411907752","doi":"https://doi.org/10.1158/1078-0432.c.7903394"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.7903394","doi":"https://doi.org/10.1158/1078-0432.c.7903394","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7903394","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.7903394","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082683623","display_name":"Lara Emily Davis","orcid":"https://orcid.org/0000-0002-6480-1611","observed_orcids":["https://orcid.org/0000-0002-6480-1611"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lara E. Davis","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6480-1611","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078174556","display_name":"Limin Zhu","orcid":"https://orcid.org/0000-0002-8723-7427","observed_orcids":["https://orcid.org/0000-0002-8723-7427"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Limin Zhu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8723-7427","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032816715","display_name":"Emile J. Latour","orcid":"https://orcid.org/0000-0002-7749-7217","observed_orcids":["https://orcid.org/0000-0002-7749-7217"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emile Latour","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7749-7217","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038205023","display_name":"Nathan P. McMahon","orcid":"https://orcid.org/0000-0002-5132-0464","observed_orcids":["https://orcid.org/0000-0002-5132-0464"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathan McMahon","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5132-0464","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050675435","display_name":"Go Nishikawa","orcid":"https://orcid.org/0000-0003-2253-7274","observed_orcids":["https://orcid.org/0000-0003-2253-7274"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Go Nishikawa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2253-7274","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049837386","display_name":"Florence Choo","orcid":"https://orcid.org/0000-0002-7904-8271","observed_orcids":["https://orcid.org/0000-0002-7904-8271"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Florence Choo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7904-8271","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085961213","display_name":"Kevin D. Nusser","orcid":"https://orcid.org/0009-0003-3644-8376","observed_orcids":["https://orcid.org/0009-0003-3644-8376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin D. Nusser","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-3644-8376","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027363296","display_name":"Jan\u00e9t Pittsenbarger","orcid":"https://orcid.org/0009-0005-6812-280X","observed_orcids":["https://orcid.org/0009-0005-6812-280X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jan\u00e9t Pittsenbarger","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-6812-280X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057957686","display_name":"Reid Burch","orcid":"https://orcid.org/0009-0000-0695-5770","observed_orcids":["https://orcid.org/0009-0000-0695-5770"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Reid Burch","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-0695-5770","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053120757","display_name":"Byung S. Park","orcid":"https://orcid.org/0000-0003-3516-7516","observed_orcids":["https://orcid.org/0000-0003-3516-7516"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Byung Park","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3516-7516","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005221518","display_name":"Gordon Brent Mills","orcid":"https://orcid.org/0000-0002-0144-9614","observed_orcids":["https://orcid.org/0000-0002-0144-9614"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon B. Mills","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0144-9614","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032760756","display_name":"Jessica L. Davis","orcid":"https://orcid.org/0000-0002-2725-1518","observed_orcids":["https://orcid.org/0000-0002-2725-1518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jessica L. Davis","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2725-1518","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045185741","display_name":"Monika Ashok Davare","orcid":"https://orcid.org/0000-0003-1802-7597","observed_orcids":["https://orcid.org/0000-0003-1802-7597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Monika Davare","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1802-7597","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5042631007","display_name":"Christopher W. Ryan","orcid":"https://orcid.org/0000-0002-4259-1123","observed_orcids":["https://orcid.org/0000-0002-4259-1123","https://orcid.org/0000-0003-1757-8311"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher W. Ryan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4259-1123","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":1.0},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.996999979019165},{"id":"https://openalex.org/keywords/metastatic-soft-tissue-sarcoma","display_name":"metastatic soft tissue sarcoma","score":0.8980000019073486},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.7680000066757202},{"id":"https://openalex.org/keywords/sequential-therapy","display_name":"sequential therapy","score":0.6119999885559082},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.7630000114440918},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9150000214576721},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.949999988079071},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.7760000228881836},{"id":"https://openalex.org/keywords/rb-phosphorylation","display_name":"retinoblastoma protein phosphorylation","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9240000247955322},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8659999966621399},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7200000286102295},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9679999947547913}],"concepts":[{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.8418115377426147},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.7644293308258057},{"id":"https://openalex.org/C136948725","wikidata":"https://www.wikidata.org/wiki/Q1458306","display_name":"Soft tissue","level":2,"score":0.4735511839389801},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4440992474555969},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.41093334555625916},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29022279381752014},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22927355766296387},{"id":"https://openalex.org/C126838900","wikidata":"https://www.wikidata.org/wiki/Q77604","display_name":"Radiology","level":1,"score":0.2061927318572998},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14820262789726257},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.1196577250957489},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.05717417597770691},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.7903394","doi":"https://doi.org/10.1158/1078-0432.c.7903394","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7903394","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.7903394","doi":"https://doi.org/10.1158/1078-0432.c.7903394","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7903394","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4410230915","https://openalex.org/W3032218688","https://openalex.org/W2954451009","https://openalex.org/W6926382705","https://openalex.org/W2115212952","https://openalex.org/W7128172369","https://openalex.org/W2413552560","https://openalex.org/W7165050362","https://openalex.org/W4399629332","https://openalex.org/W2066227041"],"abstract_inverted_index":{"AbstractPurpose:":[0],"Doxorubicin":[1],"is":[2,236],"the":[3,16,24,45,92,98,170],"first-line":[4],"treatment":[5,81],"for":[6,72,131,138],"metastatic":[7,55],"soft-tissue":[8,56],"sarcomas.":[9],"Ribociclib,":[10],"a":[11,166,187],"cyclin-dependent":[12],"kinase":[13],"4/6":[14],"intargets":[15],"retinoblastoma":[17,144,213],"pathway":[18],"to":[19,34,36,90],"induce":[20],"cell-cycle":[21,26,38],"arrest":[22],"at":[23,174],"G1\u2013S":[25],"checkpoint.":[27],"We":[28],"hypothesized":[29],"that":[30],"administering":[31],"ribociclib":[32,70,227,237],"prior":[33],"doxorubicin":[35,155,182,242],"synchronize":[37],"progression":[39],"among":[40],"tumor":[41,217],"cells":[42],"may":[43],"enhance":[44],"efficacy":[46],"of":[47,79,84,97,142,159,190,211],"doxorubicin.":[48,85],"Patients":[49],"and":[50,107,116,127,154,181,222],"Methods:":[51],"Doxorubicin-na\u00efve":[52],"patients":[53,161,172,195],"with":[54,226],"sarcoma":[57],"were":[58,125,129,206,220],"enrolled":[59,126],"in":[60,215],"this":[61],"phase":[62,94,233],"Ib":[63],"study.":[64],"Every":[65],"21":[66],"days,":[67],"subjects":[68],"received":[69],"daily":[71],"7":[73],"days":[74,78],"followed":[75,240],"by":[76,241],"3":[77],"no":[80],"before":[82],"administration":[83],"The":[86,134,231],"primary":[87],"objective":[88,108],"was":[89,140],"establish":[91],"recommended":[93,232],"II":[95,234],"dose":[96,132,148,175,235],"sequenced":[99],"drug":[100],"combination.":[101],"Secondary":[102],"objectives":[103],"included":[104],"progression-free":[105],"survival":[106],"response":[109,198,200],"rate.":[110],"Exploratory":[111],"correlative":[112],"studies":[113],"assessed":[114],"pharmacokinetic":[115,204],"pharmacodynamic":[117],"measures.":[118],"Results:":[119],"Of":[120,169],"38":[121],"screened":[122],"patients,":[123],"16":[124],"15":[128],"evaluable":[130],"determination.":[133],"most":[135],"common":[136],"reason":[137],"exclusion":[139],"lack":[141],"normal":[143],"protein":[145,214],"expression.":[146],"At":[147],"level":[149,176],"0":[150],"(ribociclib":[151,178],"400":[152,179,238],"mg":[153,180,239],"75":[156],"mg/m2),":[157,184],"four":[158],"seven":[160],"experienced":[162],"febrile":[163],"neutropenia":[164],"as":[165],"dose-limiting":[167,188],"toxicity.":[168],"eight":[171],"treated":[173],"\u22121":[177],"60":[183,243],"one":[185],"had":[186],"toxicity":[189,249],"grade":[191],"4":[192],"anemia.":[193],"Three":[194],"achieved":[196],"partial":[197],"(objective":[199],"rate,":[201],"20.0%).":[202],"Ribociclib":[203],"levels":[205],"lower":[207],"than":[208],"predicted.":[209],"Levels":[210],"phosphorylated":[212],"on-treatment":[216],"biopsy":[218],"tissue":[219],"variable":[221],"did":[223],"not":[224],"correlate":[225],"plasma":[228],"levels.":[229],"Conclusions:":[230],"mg/m2,":[244],"which":[245],"demonstrated":[246],"an":[247],"acceptable":[248],"profile.":[250]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2025-10-10T00:00:00"}